Skip to main content
. 2022 Aug 16;21(11):799–820. doi: 10.1038/s41573-022-00520-5

Fig. 3. Myeloid checkpoints and other inhibitory receptors expressed by macrophages.

Fig. 3

a | Overview of myeloid checkpoints and inhibitory receptors expressed by tumour-associated macrophages (TAMs) and their ligands expressed on tumour cells or cell debris. These include the receptor/ligand pairs signal regulatory protein-α (SIRPα)–CD47, LILRB1–HLA1, sialic acid-binding immunoglobulin-like lectin 10 (SIGLEC10)–CD24, and PD1–PDL1, which inhibit phagocytosis, and macrophage receptor with collagenous structure (MARCO), CD169 and mannose receptor scavenger receptors. Clever 1, triggering receptor expressed on myeloid cells 2 (TREM2) and P-selectin glycoprotein ligand 1 (PSGL1) are also depicted. Targeting of Clever 1 and TREM2 does not specifically interfere with phagocytosis but with immunosuppressive activation. b | In strategies featuring the use of therapeutic antibodies, such as anti-CD20 or anti-epithelial growth factor receptor (EGFR), combinatorial use of anti-CD47 enhances antibody-dependent cellular phagocytosis (ADCP) and increases antigen presentation to T cells. c | Bispecific CD47 antibodies are designed to recognize CD47 and tumour-associated antigens (such as CD20 or PDL1), which enhances selective blocking of CD47 on tumour cells, avoiding on-target toxicity due to recognition of CD47 on red blood cells and platelets. ADCC, antibody-dependent cellular cytotoxicity; MHC II, MHC class II.